Radiation-induced upregulation of telomerase activity escapes PI3-kinase inhibition in two malignant glioma cell lines

International Journal of Oncology

Volumn 43, Issue 2, 2013, Pages 375-382

  Millet, Pascal ^a,e   Granotier, C ^a,b,c,d   Etienne, O ^a,b,c,d   Boussin, F D ^a,b,c,d  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b Universite Paris Sud   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Glioblastoma; Glioma; PI3 kinase; Radiation; Radiosensitization; Telomerase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; HISTONE H2AX; PHOSPHATIDYLINOSITOL 3 KINASE; TELOMERASE;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION; RADIATION PROTECTION; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL LINE, TUMOR; CHROMONES; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; ENZYME ACTIVATION; ENZYME INHIBITORS; G2 PHASE CELL CYCLE CHECKPOINTS; GLIOMA; HUMANS; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TELOMERASE; UP-REGULATION;

EID: 84879647178     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1970     Document Type: Article

References (88)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
2. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
3. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
4. Koukourakis GV, Kouloulias V, Zacharias G, et al: Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules 14: 1561-1577, 2009.
5. Kondo Y, Hollingsworth EF and Kondo S: Molecular targeting for malignant gliomas (Review). Int J Oncol 24: 1101-1109, 2004.
6. Tanaka H, Yoshida M, Tanimura H, et al: The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 17: 3272-3281, 2011.
7. Jiang Z, Pore N, Cerniglia GJ, et al: Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 67: 4467-4473, 2007. (Pubitemid 46815097)
8. Mason WP, Belanger K, Nicholas G, et al: A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. J Neurooncol 107: 343-349, 2011.
9. Fassl A, Tagscherer KE, Richter J, et al: Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1. Oncogene 31: 4698-4708, 2012.
10. Stockhausen MT, Broholm H, Villingshoj M, et al: Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Exp Cell Res 317: 1513-1526, 2011.
11. Ji XM, Xie CH, Fang MH, et al: Efficient inhibition of human telomerase activity by antisense oligonucleotides sensitizes cancer cells to radiotherapy. Acta Pharmacol Sin 27: 1185-1191, 2006. (Pubitemid 44410999)
12. Chakravarti A, Zhai G, Suzuki Y, et al: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22: 1926-1933, 2004. (Pubitemid 41095185)
13. Kao GD, Jiang Z, Fernandes AM, Gupta AK and Maity A: Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem 282: 21206-21212, 2007. (Pubitemid 47099899)
14. Gallia GL, Tyler BM, Hann CL, et al: Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther 8: 386-393, 2009.
15. Chautard E, Loubeau G, Tchirkov A, et al: Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neurooncology 12: 434-443, 2010.
16. Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8: 187-198, 2008. (Pubitemid 351688437)
17. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS and Pieper RO: Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 61: 6674-6678, 2001. (Pubitemid 32896484)
18. Suzuki Y, Shirai K, Oka K, et al: Higher pAkt expression predicts a significant worse prognosis in glioblastomas. J Radiat Res 51: 343-348, 2010.
19. Ermoian RP, Furniss CS, Lamborn KR, et al: Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 8: 1100-1106, 2002. (Pubitemid 34517646)
20. Choe G, Horvath S, Cloughesy TF, et al: Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63: 2742-2746, 2003. (Pubitemid 36667143)
21. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN and von Deimling A: Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7: 871-875, 1997. (Pubitemid 27346731)
22. Sugawa N, Ekstrand AJ, James CD and Collins VP: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87: 8602-8606, 1990.
23. Huang HS, Nagane M, Klingbeil CK, et al: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272: 2927-2935, 1997. (Pubitemid 27053343)
24. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G and Stokoe D: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 8: 1195-1198, 1998. (Pubitemid 28494720)
25. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275: 1943-1947, 1997. (Pubitemid 27148818)
26. Myers MP, Pass I, Batty IH, et al: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 95: 13513-13518, 1998. (Pubitemid 28523003)
27. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE and Fuller GN: Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25: 55-57, 2000. (Pubitemid 30257036)
28. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X and Holland EC: Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 12: 889-901, 2003. (Pubitemid 37352782)
29. Smith JS, Tachibana I, Passe SM, et al: PTEN mutation, EGFR amplification and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256, 2001. (Pubitemid 32816199)
30. Knobbe CB, Merlo A and Reifenberger G: Pten signaling in gliomas. Neurooncology 4: 196-211, 2002.
31. Koul D: PTEN signaling pathways in glioblastoma. Cancer Biol Ther 7: 1321-1325, 2008.
32. Li HF, Kim JS and Waldman T: Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 4: 43, 2009.
33. Nakamura JL, Karlsson A, Arvold ND, et al: PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol 71: 215-222, 2005. (Pubitemid 40372948)
34. Turriziani M, Di Giacomo AM, Cardillo A, et al: Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro. Anticancer Res 23: 4561-4569, 2003. (Pubitemid 38173868)
35. Wang X, Liu Y, Chow LS, et al: Regulation of telomerase activity by gamma-radiation in nasopharyngeal carcinoma cells. Anticancer Res 20: 433-437, 2000. (Pubitemid 30189791)
36. Perez Mdel R, Dubner D, Michelin S, Leteurtre F, Carosella ED and Gisone PA: Radiation-induced upregulation of telomerase in KG1a cells is influenced by dose-rate and radiation quality. Int J Radiat Biol 78: 1175-1183, 2002. (Pubitemid 35462146)
37. Wong KK, Chang S, Weiler SR, et al: Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet 26: 85-88, 2000.
38. Falchetti ML, Pallini R, D'Ambrosio E, et al: In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme. Int J Cancer 88: 895-901, 2000.
39. Huang F, Kanno H, Yamamoto I, Lin Y and Kubota Y: Correlation of clinical features and telomerase activity in human gliomas. J Neurooncol 43: 137-142, 1999. (Pubitemid 29445641)
40. Harada K, Kurisu K, Tahara H, Tahara E and Ide T: Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. J Neurosurg 93: 618-625, 2000. (Pubitemid 32799296)
41. Fukushima T, Yoshino A, Katayama Y, Watanabe T, Kusama K and Moro I: Prediction of clinical course of diffusely infiltrating astrocytomas from telomerase expression and quantitated activity level. Cancer Lett 187: 191-198, 2002. (Pubitemid 35279349)
42. Boldrini L, Pistolesi S, Gisfredi S, et al: Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol 28: 1555-1560, 2006.
43. Wesbuer S, Lanvers-Kaminsky C, Duran-Seuberth I, et al: Association of telomerase activity with radio- and chemosensitivity of neuroblastomas. Radiat Oncol 5: 66, 2010.
44. Merle P, Evrard B, Petitjean A, et al: Telomere targeting with a new G4 ligand enhances radiation-induced killing of human glioblastoma cells. Mol Cancer Ther 10: 1784-1795, 2011.
45. Marian CO, Cho SK, McEllin BM, et al: The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 16: 154-163, 2010.
46. Zhou FX, Liao ZK, Dai J, et al: Radiosensitization effect of zidovudine on human malignant glioma cells. Biochem Biophys Res Commun 354: 351-356, 2007. (Pubitemid 46161335)
47. Kang SS, Kwon T, Kwon DY and Do SI: Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 274: 13085-13090, 1999.
48. Zhou C, Bae-Jump VL, Whang YE, Gehrig PA and Boggess JF: The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecol Oncol 101: 305-310, 2006.
49. Uziel O, Fenig E, Nordenberg J, et al: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 92: 1881-1891, 2005. (Pubitemid 40826137)
50. Leteurtre F, Li X, Gluckman E and Carosella ED: Telomerase activity during the cell cycle and in gamma-irradiated hematopoietic cells. Leukemia 11: 1681-1689, 1997. (Pubitemid 27458607)
51. Finnon P, Silver AR and Bouffler SD: Upregulation of telomerase activity by X-irradiation in mouse leukaemia cells is independent of Tert, Terc, Tnks and Myc transcription. Carcinogenesis 21: 573-578, 2000. (Pubitemid 30214009)
52. Hande MP, Balajee AS and Natarajan AT: Induction of telomerase activity by UV-irradiation in Chinese hamster cells. Oncogene 15: 1747-1752, 1997. (Pubitemid 27466716)
53. Hyeon Joo O, Hande MP, Lansdorp PM and Natarajan AT: Induction of telomerase activity and chromosome aberrations in human tumour cell lines following X-irradiation. Mutat Res 401: 121-131, 1998. (Pubitemid 28293844)
54. Ram R, Uziel O, Eldan O, et al: Ionizing radiation upregulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway. Clin Cancer Res 15: 914-923, 2009.
55. Lefranc F, Rynkowski M, DeWitte O and Kiss R: Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg 34: 3-35, 2009.
56. Cully M, You H, Levine AJ and Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192, 2006. (Pubitemid 43292562)
57. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
58. Vlahos CJ, Matter WF, Hui KY and Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248, 1994.
59. Menet A, Speth C, Larcher C, et al: Epstein-Barr virus infection of human astrocyte cell lines. J Virol 73: 7722-7733, 1999. (Pubitemid 29383256)
60. Pennarun G, Granotier C, Gauthier LR, et al: Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands. Oncogene 24: 2917-2928, 2005. (Pubitemid 40675523)
61. Walker SM, Leslie NR, Perera NM, Batty IH and Downes CP: The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J 379: 301-307, 2004. (Pubitemid 38570102)
62. Sano T, Asai A, Mishima K, Fujimaki T and Kirino T: Telomerase activity in 144 brain tumours. Br J Cancer 77: 1633-1637, 1998. (Pubitemid 28230464)
63. Liang J and Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2: 339-345, 2003.
64. Olive PL: Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol 75: 355-373, 2004.
65. Nowak E, Etienne O, Millet P, et al: Radiation-induced H2AX phosphorylation and neural precursor apoptosis in the developing brain of mice. Radiat Res 165: 155-164, 2006. (Pubitemid 43153128)
66. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868, 1998. (Pubitemid 28124064)
67. Fernandez-Capetillo O, Lee A, Nussenzweig M and Nussenzweig A: H2AX: the histone guardian of the genome. DNA Repair 3: 959-967, 2004. (Pubitemid 38997938)
68. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M and Jeggo PA: ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 64: 2390-2396, 2004. (Pubitemid 38523891)
69. Hiraga S, Ohnishi T, Izumoto S, et al: Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res 58: 2117-2125, 1998. (Pubitemid 28232897)
70. Tchirkov A, Rolhion C, Kemeny JL, et al: Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br J Cancer 88: 516-520, 2003. (Pubitemid 36363360)
71. Shervington A, Patel R, Lu C, et al: Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res 1134: 45-52, 2007. (Pubitemid 46135546)
72. Hirao T, Urata Y, Kageyama K, et al: Dehydroepiandrosterone augments sensitivity to gamma-ray irradiation in human H4 neuroglioma cells through down-regulation of Akt signaling. Free Radic Res 42: 957-965, 2008.
73. Ramaswamy S, Nakamura N, Vazquez F, et al: Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96: 2110-2115, 1999. (Pubitemid 29117876)
74. Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res 61: 2105-2111, 2001.
75. Liang J, Zubovitz J, Petrocelli T, et al: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153-1160, 2002. (Pubitemid 35175971)
76. Rosenzweig KE, Youmell MB, Palayoor ST and Price BD: Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 3: 1149-1156, 1997. (Pubitemid 27319761)
77. Park JK, Jung HY, Park SH, et al: Combination of PTEN and gamma-ionizing radiation enhances cell death and G(2)/M arrest through regulation of AKT activity and p21 induction in non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 70: 1552-1560, 2008. (Pubitemid 351417776)
78. Toulany M, Kehlbach R, Florczak U, et al: Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 7: 1772-1781, 2008.
79. Shtivelman E, Sussman J and Stokoe D: A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol 12: 919-924, 2002. (Pubitemid 34689227)
80. Lee SR, Park JH, Park EK, Chung CH, Kang SS and Bang OS: Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. J Cell Physiol 205: 270-277, 2005. (Pubitemid 41428910)
81. He L, Yang X, Cao X, Liu F, Quan M and Cao J: Casticin induces growth suppression and cell cycle arrest through activation of FOXO3a in hepatocellular carcinoma. Oncol Rep 29: 103-108, 2013.
82. Chung J, Khadka P and Chung IK: Nuclear import of hTERT requires a bipartite nuclear localization signal and Akt-mediated phosphorylation. J Cell Sci 125: 2684-2697, 2012.
83. Neuhof D, Zwicker F, Kuepper JH, Debus J and Weber KJ: Activation of telomerase by ionizing radiation: differential response to the inhibition of DNA double-strand break repair by abrogation of poly (ADP-ribosyl)ation, by LY294002, or by Wortmannin. Int J Radiat Oncol Biol Phys 69: 887-894, 2007. (Pubitemid 47418416)
84. Fu W, Begley JG, Killen MW and Mattson MP: Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 274: 7264-7271, 1999.
85. Blackburn EH: Switching and signaling at the telomere. Cell 106: 661-673, 2001.
86. Akiyama M, Yamada O, Kanda N, et al: Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett 178: 187-197, 2002. (Pubitemid 34178544)
87. Masutomi K, Possemato R, Wong JM, et al: The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci USA 102: 8222-8227, 2005. (Pubitemid 40800070)
88. Ferrandon S, Saultier P, Carras J, et al: Telomere profiling: toward glioblastoma personalized medicine. Mol Neurobiol 47: 64-76, 2013.